Comparative Evaluation of Iron Deficiency among Obese and Non-obese Children

Mr Sharif1, M Madani2, F Tabatabaie3

  • 1Trauma Research Center, Kashan University of Medical Sciences, Kashan, Iran.

Insights

Obese children show lower serum iron levels and higher total iron-binding capacity compared to non-obese children. Ferritin levels were similar, suggesting obesity may influence iron status markers.

Area of Science:

  • Pediatric Endocrinology
  • Nutritional Science
  • Hematology

Background:

  • Obesity in children is linked to increased risk of micronutrient deficiencies, particularly iron deficiency.
  • Existing research shows discrepancies in understanding iron deficiency prevalence and markers in obese pediatric populations.
  • This study addresses the need to evaluate iron deficiency specifically in obese children.

Purpose of the Study:

  • To investigate and compare iron deficiency indicators between obese children and their non-obese peers.
  • To analyze serum iron, total iron-binding capacity (TIBC), and plasma ferritin levels in relation to childhood obesity.
  • To determine the prevalence and characteristics of iron deficiency in obese versus non-obese children.

Main Methods:

  • A case-control study involving 100 children aged 5-15 years.
  • Cases comprised 50 obese children, and controls included 50 non-obese children.
  • Biochemical analysis of serum iron, TIBC, and plasma ferritin (ELISA) was performed on blood samples.

Main Results:

  • Obese children exhibited significantly lower mean serum iron (52.38 µg/dL vs. 64.50 µg/dL) and higher TIBC (434.80 µg/dL vs. 382.28 µg/dL) compared to controls (P<0.02 and P<0.008, respectively).
  • Plasma ferritin levels were comparable between obese (70.56 ng/mL) and non-obese (68.06 ng/mL) children (P=0.79).
  • While 8.3% of obese children had ferritin <15 ng/mL, 100% of iron-deficient non-obese children had ferritin <15 ng/mL (P<0.001).

Conclusions:

  • Obese children demonstrate lower serum iron and higher TIBC, indicating altered iron metabolism.
  • Similar ferritin levels between groups may be attributed to the inflammatory state associated with obesity.
  • The study suggests considering higher ferritin reference values for obese children due to potential obesity-induced inflammation.
Abstract

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
351
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.6K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
310
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
425